People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Par Health, Inc. | — | Pharmaceuticals | Growth/Late | $763.0M | $6.8B | 2025 |
| Endo, Inc. | — | Pharmaceuticals | Series D+ | $170.6M | $2.0B | 2024 |
Matthew Maletta at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Maletta on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Heffernan | 1 | 5 |
| Patrick Barry | 1 | 4 |
| Paul Efron | 1 | 3 |
| Mark Bradley | 1 | 3 |
| Scott Hirsch | 1 | 2 |
| Jack Boyle | 1 | 2 |
| Kass Harrold | 1 | 1 |
| Matthew Stober | 1 | 1 |
| Joshua Murray | 1 | 1 |
| Stephen Welch | 1 | 1 |
| Jonathan Zinman | 1 | 1 |
| Andrew Gonce | 1 | 1 |
| Paul Herendeen | 1 | 1 |
| Marc Yoskowitz | 1 | 1 |
| Blaise Coleman | 1 | 1 |
| Sophia Langlois | 1 | 1 |
| Frank Raciti | 1 | 1 |
| Andy Pasternak | 1 | 1 |
| Teresa Sanzottera | 1 | 1 |
| Jake Longenecker | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.